Πρωτεύουσες καρτέλες
Ο κατάλογος των δημοσιεύσεων είναι ενδεικτικός και μπορεί να μην περιλαμβάνει το σύνολο των δημοσιεύσεων.
Variants in clock genes could be associated with lower risk of type 2 diabetes in an elderly Greek population..
Maturitas. 152, 20-25.
(2021).
Pharmacogenetics of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management..
Curr Pharm Des. 27(8), 1025-1034.
(2021).
Vitamin D receptor Fokl polymorphism is a determinant of both maternal and neonatal vitamin D concentrations at birth..
J Steroid Biochem Mol Biol. 199, 105568.
(2020).
Characterizing neonatal vitamin D deficiency in the modern era: A maternal-neonatal birth cohort from Southern Europe..
J Steroid Biochem Mol Biol. 198, 105555.
(2020).
Association between CUBN gene variants, type 2 diabetes and vitamin D concentrations in an elderly Greek population..
J Steroid Biochem Mol Biol. 198, 105549.
(2020).
Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?.
J Diabetes Sci Technol. 14(4), 745-747.
(2020).
Rising Glucagon-Like Peptide 1 Concentrations After Parathyroidectomy in Patients With Primary Hyperparathyroidism..
J Surg Res. 245, 22-30.
(2019).
The combined effect of vitamin D and parathyroid hormone concentrations on glucose homeostasis in older patients with prediabetes: A cross-sectional study..
Diab Vasc Dis Res. 15(2), 150-153.
(2018).
Orthodox religious fasting as a medical nutrition therapy for dyslipidemia: where do we stand and how far can we go?.
Eur J Clin Nutr. 72(4), 474-479.
(2018).
The beta-cell death in long-term type 2 diabetes mellitus: never say never again..
Minerva Endocrinol.
(2018).
Deconvoluting the Biological Roles of Vitamin D-Binding Protein During Pregnancy: A Both Clinical and Theoretical Challenge..
Front Endocrinol (Lausanne). 9, 259.
(2018).
Effects of Orthodox religious fasting on human health: a systematic review..
Eur J Nutr. 56(8), 2439-2455.
(2017).
Pharmacogenetics of Glucagon-like Peptide-1 Agonists for the Treatment of Type 2 Diabetes Mellitus..
Curr Clin Pharmacol. 12(4), 202-209.
(2017).